The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)

Tue, 08th May 2018 13:13

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.

Raglan Road Capital Ltd is owned by former Non-Executive Director Cathal Friel and his wife Pamela Iyer.

The shares were sold at a price of 17.00 pence each, giving a total value of GBP1.4 million.

Following the deal, Raglan Road holds 24.7 million Amryt shares, just under 9.0% of the entire company.

Amryt said Friel and his company have entered into a two-year restriction on the sale of their shares.

Over the first twelve months, they will not sell shares apart from in "very limited circumstances". For the following twelve months, they can only sell shares if done through Shore Capital Stockbrokers Ltd.

Amryt shares were 2.6% higher on Tuesday at 17.96 pence each.

Related Shares

More News
11 Jan 2022 14:39

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

22 Nov 2021 11:37

Amryt to delist from AIM, concentrate on Nasdaq trading

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday,...

9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

19 Oct 2021 15:54

Amryt Pharma granted another two US patents

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S...

14 Sep 2021 07:32

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.